The present invention relates to a method for purifying key intermediates of Citalopram, i.e. 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxymethylbenzonitrile and a salt thereof. The method comprises dissolving crude 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxymethylbenzonitrile (compound of formula I containing formaldehyde impurity) with an organic solvent, adding a washing solution, controlling the temperature, stirring, leaving to stand for layering, and removing the aqueous layer, so as to obtain a purified organic solution of 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxymethylbenzonitrile. The method provided by the present invention can effectively remove aldehyde group-containing impurities in the intermediate. The method of the present invention has the advantages of simple operation, cheap raw materials and mild conditions, and is suitable for large-scale industrial production.

The present invention relates to a novel phenoxyacetic acid derivative represented by the general formula (I), preparation method thereof and use of a pharmaceutical composition containing the derivative in preparing a medicament for treating diabetes and metabolic syndrome. The phenoxyacetic acid derivatives have excellent in vivo hypoglycemic activity, which can be used for preventing or treating diabetes.

The present invention relates to a novel phenoxyacetic acid derivative represented by the general formula (I), preparation method thereof and use of a pharmaceutical composition containing the derivative in preparing a medicament for treating diabetes and metabolic syndrome. The phenoxyacetic acid derivatives have excellent in vivo hypoglycemic activity, which can be used for preventing or treating diabetes.

The present invention provides a compound having the structure:

##STR00001## wherein R.sub.1 is (C.sub.2-C.sub.12 alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl); R.sub.2 is H, halogen, NO.sub.2, CN, CF.sub.3, CF.sub.2H, CH.sub.2OCH.sub.3, CF.sub.2CH.sub.3, CF.sub.2OCH.sub.3, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), -(cycloalkylalkyl), -(heteroalkyl), -(heterocycle), -(heterocycloalkyl), -(aryl), -(heteroaryl), -(hydroxyalkyl), -(haloalkyl), -(alkylaryl), OH, O-(alkyl), O-(alkenyl), O-(alkynyl), O-(haloalkyl), O-(aryl), O-(heteroaryl), OCF.sub.3, SH, S-(alkyl), S-(alkenyl), S-(alkynyl), S-(aryl), S-(heteroaryl), NH.sub.2, NH-(alkyl), NH-(alkenyl), NH-(alkynyl), N-(alkyl).sub.2, NH-(aryl), NH-(heteroaryl), CO.sub.2H, CO.sub.2-(alkyl), C(O)NH.sub.2, C(O)NH-(alkyl), C(O)NH-(aryl), SO.sub.2CH.sub.3 or Si(CH.sub.3) .sub.3; R.sub.3 is OCH.sub.3, OCH.sub.2CH.sub.3, F or Cl; and R.sub.4 is OCH.sub.3, OCH.sub.2CH.sub.3 or SCH.sub.3; wherein when R.sub.1 is CH.sub.2CH.sub.3, R.sub.3 is OCH.sub.3, and R.sub.4 is OCH.sub.3, then R.sub.2 is other than H, CH.sub.3, CH.sub.2CH.sub.3, CH.sub.2CH.sub.2CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2CH.sub.2CH.sub.2CH.sub.3, CH.sub.2OH, CH(OH) CH.sub.3, OH, OCH.sub.2CH.sub.3, OCH.sub.2CH.sub.2CH.sub.3, OCH(CH.sub.3).sub.2, SCH.sub.3, SCH.sub.2CH.sub.3, SCH.sub.2CH.sub.2CH.sub.3, NO.sub.2, NH.sub.2, F, Cl, Br or I,
or a pharmaceutically acceptable salt thereof.

The present invention provides a compound having the structure:

##STR00001## wherein R.sub.1 is (C.sub.2-C.sub.12 alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl); R.sub.2 is H, halogen, NO.sub.2, CN, CF.sub.3, CF.sub.2H, CH.sub.2OCH.sub.3, CF.sub.2CH.sub.3, CF.sub.2OCH.sub.3, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), -(cycloalkylalkyl), -(heteroalkyl), -(heterocycle), -(heterocycloalkyl), -(aryl), -(heteroaryl), -(hydroxyalkyl), -(haloalkyl), -(alkylaryl), OH, O-(alkyl), O-(alkenyl), O-(alkynyl), O-(haloalkyl), O-(aryl), O-(heteroaryl), OCF.sub.3, SH, S-(alkyl), S-(alkenyl), S-(alkynyl), S-(aryl), S-(heteroaryl), NH.sub.2, NH-(alkyl), NH-(alkenyl), NH-(alkynyl), N-(alkyl).sub.2, NH-(aryl), NH-(heteroaryl), CO.sub.2H, CO.sub.2-(alkyl), C(O)NH.sub.2, C(O)NH-(alkyl), C(O)NH-(aryl), SO.sub.2CH.sub.3 or Si(CH.sub.3) .sub.3; R.sub.3 is OCH.sub.3, OCH.sub.2CH.sub.3, F or Cl; and R.sub.4 is OCH.sub.3, OCH.sub.2CH.sub.3 or SCH.sub.3; wherein when R.sub.1 is CH.sub.2CH.sub.3, R.sub.3 is OCH.sub.3, and R.sub.4 is OCH.sub.3, then R.sub.2 is other than H, CH.sub.3, CH.sub.2CH.sub.3, CH.sub.2CH.sub.2CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2CH.sub.2CH.sub.2CH.sub.3, CH.sub.2OH, CH(OH) CH.sub.3, OH, OCH.sub.2CH.sub.3, OCH.sub.2CH.sub.2CH.sub.3, OCH(CH.sub.3).sub.2, SCH.sub.3, SCH.sub.2CH.sub.3, SCH.sub.2CH.sub.2CH.sub.3, NO.sub.2, NH.sub.2, F, Cl, Br or I,
or a pharmaceutically acceptable salt thereof.

Disclosed in the present disclosure is a Dezocine analog, and particularly disclosed are compounds represented by formula (I), (II) and (III), a pharmaceutically acceptable salt or tautomer thereof. ##STR00001##

Disclosed in the present disclosure is a Dezocine analog, and particularly disclosed are compounds represented by formula (I), (II) and (III), a pharmaceutically acceptable salt or tautomer thereof. ##STR00001##

The present invention includes methods/processes and intermediates for preparing compounds having structural Formula (XI):

##STR00001## wherein Y is C.sub.1-C.sub.12 alkylene or C.sub.1-C.sub.12 alkenylene; and R.sup.8 and R.sup.12 are independently C.sub.1-C.sub.12 alkyl.

The present invention includes methods/processes and intermediates for preparing compounds having structural Formula (XI):

##STR00001## wherein Y is C.sub.1-C.sub.12 alkylene or C.sub.1-C.sub.12 alkenylene; and R.sup.8 and R.sup.12 are independently C.sub.1-C.sub.12 alkyl.

The present disclosure provides phenalkylamine compounds and their use in treating medical disorders, such as psychiatric diseases and disorders. Pharmaceutical compositions and methods of making various phenalkylamine compounds are provided.